US2023414494A1PendingUtilityA1

Compositions and methods for the treatment of presbyopia

82
Assignee: LENZ THERAPEUTICS INCPriority: Aug 28, 2013Filed: Sep 12, 2023Published: Dec 28, 2023
Est. expiryAug 28, 2033(~7.1 yrs left)· nominal 20-yr term from priority
Inventors:Gerald Horn
A61K 9/0048A61K 9/08A61K 47/02A61K 47/26A61K 47/38A61K 31/439A61P 27/10A61K 31/4409A61K 47/32A61K 45/06A61K 47/10A61K 47/34
82
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Provided herein is an ophthalmological composition and methods for the treatment of presbyopia. In some embodiments, the ophthalmological composition comprises aceclidine and brimonidine.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . An ophthalmological composition comprising aceclidine and brimonidine. 
     
     
         2 . The ophthalmological composition of  claim 1 , wherein when administered to an eye of a subject the ophthalmological composition results in reduced eye redness of the subject compared to an otherwise identical ophthalmological composition comprising aceclidine as the sole active agent. 
     
     
         3 . The ophthalmological composition of  claim 1 , wherein the ophthalmological composition comprises a pH from about 4.0 to about 8.0. 
     
     
         4 . The ophthalmological composition of  claim 1 , wherein the ophthalmological composition has an initial viscosity of at least 20 centipoises (“cps”) at a shear of 1/s, the initial viscosity being the viscosity of the ophthalmological composition on upon administration to the eye. 
     
     
         5 . The ophthalmological composition of  claim 1 , wherein after administration to an eye forms an administered composition having a first viscosity, the first viscosity being the viscosity of the administered ophthalmological composition between eyelid blinks. 
     
     
         6 . The ophthalmological composition of  claim 5 , wherein the first viscosity is between 10 cps and 100 cps. 
     
     
         7 . The ophthalmological composition of  claim 5 , wherein the administered composition has a second viscosity, the second viscosity being the viscosity of the administered ophthalmological composition during an eyelid blink. 
     
     
         8 . The ophthalmological composition of  claim 7 , wherein the second viscosity is 30 cps or less. 
     
     
         9 . The ophthalmological composition of  claim 7 , wherein when administered to the eye of a subject an increased residence time of aceclidine on the eye is produced. 
     
     
         10 . The ophthalmological composition of  claim 1 , wherein the ophthalmological composition is free of a preservative. 
     
     
         11 . The ophthalmological composition of  claim 7 , wherein the ophthalmological composition is free of a preservative. 
     
     
         12 . The ophthalmological composition of  claim 1 , wherein the ophthalmological composition is free of benzalkonium ion. 
     
     
         13 . The ophthalmological composition of  claim 7 , wherein the ophthalmological composition is free of benzalkonium ion. 
     
     
         14 . A method of treating presbyopia comprising administering to an eye of a subject in need thereof an ophthalmological composition comprising aceclidine and brimonidine. 
     
     
         15 . The method of  claim 14 , wherein the ophthalmological composition has an initial viscosity of at least 20 cps at a shear of 1/s, the initial viscosity being the viscosity of the ophthalmological composition on upon administration to the eye. 
     
     
         16 . The method of  claim 14 , wherein after administration to an eye forms an administered composition having a first viscosity, the first viscosity being the viscosity of the administered ophthalmological composition between eyelid blinks. 
     
     
         17 . The ophthalmological composition of  claim 16 , wherein the first viscosity is between 10 cps and 100 cps. 
     
     
         18 . The method of  claim 16 , wherein the administered composition has a second viscosity, the second viscosity being the viscosity of the administered ophthalmological composition during an eyelid blink that is different from the first viscosity. 
     
     
         19 . The ophthalmological composition of  claim 18 , wherein the second viscosity is 30 cps or less. 
     
     
         20 . The method of  claim 14 , wherein the ophthalmological composition is free of benzalkonium ion.

Join the waitlist — get patent alerts

Track US2023414494A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.